Research on Guardant Health's Guardant360 liquid biopsy test has shown that its data can be used to make treatment decisions for patients with manageable metastatic colorectal cancer. Guardant360 can select people for targeted therapy, determine which patients respond to treatment, and identify genetic changes that predict resistance.